Glenmark Pharma’s revenue and EBITDA was in-line with our estimate where Adj. PAT beat our estimate due to lower-than-expected depreciation expense.We believe the upcoming launches of Ryaltris in multiple new markets and the anticipated filing of Envafolimab in over 20 markets are expected to provide a future boost.